Your browser doesn't support javascript.

Biblioteca Virtual em Saúde


Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:


Adicionar mais destinatários
| |

Recombinant Leishmania eukaryotic elongation factor-1 beta protein: A potential diagnostic antigen to detect tegumentary and visceral leishmaniasis in dogs and humans.

Santos, Thaís T O; Cardoso, Mariana S; Machado, Amanda S; Siqueira, Williane F; Ramos, Fernanda F; Oliveira-da-Silva, João A; Tavares, Grasiele S V; Lage, Daniela P; Costa, Lourena E; de Freitas, Camila S; Martins, Vívian T; Bandeira, Raquel S; Chávez-Fumagalli, Miguel A; Lyon, Sandra; Moreira, Ricardo L F; de Magalhães-Soares, Danielle F; Silveira, Julia A G; Tupinambás, Unaí; Caligiorne, Rachel B; Chaves, Ana Thereza; Rocha, Manoel O C; Fujiwara, Ricardo T; Coelho, Eduardo A F.
Microb Pathog; 137: 103783, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31600536
The laboratorial diagnosis of leishmaniasis is based on parasitological methods, which are invasive, present high cost, require laboratorial infrastructure and/or trained professionals; as well as by immunological methods, which usually present variable sensitivity and/or specificity, such as when they are applied to identify asymptomatic cases and/or mammalian hosts presenting low levels of antileishmanial antibodies. As consequence, new studies aiming to identify more refined antigens to diagnose visceral (VL) and tegumentary (TL) leishmaniasis are urgently necessary. In the present work, the Leishmania eukaryotic elongation factor-1 beta (EF1b) protein, which was identified in L. infantum protein extracts by antibodies in VL patients' sera, was cloned and its recombinant version (rEF1b) was expressed, purified and tested as a diagnostic marker for VL and TL. The post-therapeutic serological follow-up was also evaluated in treated and untreated VL and TL patients, when anti-rEF1b antibody levels were measured before and after treatment. Results showed that rEF1b was highly sensitive and specific to diagnose symptomatic and asymptomatic canine VL, as well as human TL and VL. In addition, low cross-reactivity was observed when sera from healthy subjects or leishmaniasis-related diseases patients were tested. The serological follow-up showed also that rEF1b-specific antibodies declined significantly after treatment, suggesting that this protein could be also evaluated as a prognostic marker for human leishmaniasis.
Selo DaSilva